MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
European Journal of Cancer
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

655 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
655 works in the cohort · of 4,299,418page 13 of 14

Labels cover 1 of 655 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 655 of 655 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

fundno affno abstractunlabeled
Psychometric validation of the Danish BREAST-Q reconstruction module
Cecilie Balslev Willert, Knud Kristensen, Pernille Envold Bidstrup, Lene Mellemkjær, Niels Kroman, Anne‐Marie Gerdes +1 more
2024· article· en· European Journal of Cancer· Medicine
distilled prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Corrigendum to “Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study” [Eur J Cancer 213 (December) (2024) 115078]
Arun Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung +13 more
2025· article· en· European Journal of Cancer· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
0
citations
affno abstractunlabeled
A randomized, double-blind, phase III study in India to evaluate efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) in comparison with Perjeta® (pertuzumab) in patients with HER2-positive metastatic breast cancer
Rushabh Kothari, Manish Doshi, P. Chaithanya, S.C. Thungappa, A. Kumar, K.M. Mallavarapu +13 more
2024· article· en· European Journal of Cancer· Immunology and Microbiology
distilled prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
[no title]
Patti Byron
2005· letter· en· European Journal of Cancer· Health Professions
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
0
citations
← previousnext →

How this was built: Screen · Findings · About